The (Cost-)Effectiveness of Generalist Versus Specialist Treatment for Severe Personality Disorders'
Launched by ARKIN · Jan 17, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to find out if generalist treatment for severe personality disorders is just as effective as specialist treatment. Participants will be randomly assigned to receive either generalist treatment, which is based on personalized care principles, or specialist treatment that includes specific therapies like Mentalization-Based Treatment (MBT) and Schema Therapy (ST). The study aims to see if patients receiving generalist treatment can improve their personality functioning at least as well as those receiving specialist care. Additionally, researchers want to understand which patient characteristics might predict who will benefit more from either type of treatment.
To be eligible for this trial, participants need to meet specific criteria, including having a severe personality disorder as defined by the DSM-5 guidelines. They should be aged 18 or older and capable of participating in the study. Participants will complete questionnaires and interviews at various points throughout the treatment to help track their progress. This trial is currently recruiting participants and aims to provide valuable insights into the effectiveness of different treatment approaches for severe personality disorders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 'severe' or 'extreme' personality disorder (PD) according to the alternative model for PDs
- Exclusion Criteria:
- • IQ \< 75
- • legal incapacity
- • Any mental state disorder that requires prior treatment
About Arkin
Arkin is a pioneering clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the healthcare sector. With a focus on enhancing patient outcomes through rigorous research and development, Arkin specializes in designing, conducting, and managing clinical trials across various therapeutic areas. The organization is committed to upholding the highest ethical standards and regulatory compliance while fostering collaboration with healthcare professionals, regulatory bodies, and industry partners. By leveraging cutting-edge technology and data-driven insights, Arkin aims to accelerate the development of safe and effective treatments, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Halsteren, Noord Brabant, Netherlands
Helmond, Noord Brabant, Netherlands
Amsterdam, Noord Holland, Netherlands
Almelo, Overijssel, Netherlands
Zeist, Utrecht, Netherlands
Patients applied
Trial Officials
Henricus L. Van, Dr.
Principal Investigator
Arkin NPI
Joost Hutsebaut, Prof. dr.
Study Director
Tilburg University; GGZ de Viersprong
Nathan Bachrach, Dr.
Study Chair
Tilburg University; GGZ Oost-Brabant
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported